Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...


Key Patent Granted For AAVLife’s Gene-Therapy Program to Treat Cardiomyopathy in Friedreich’s Ataxia


"As this recently issued patent indicates, AAVLife is building strong intellectual-property protection at the same time we are steadily progressing our R&D toward an urgently needed therapy,” said Amber Salzman, Chief Executive Officer of AAVLife.

Read More:  Key Patent Granted for AAVLife's Gene-Therapy Program to Treat Cardiomyopathy in Friedreich's ataxia

About the Author

Jen Farmer

Jen Farmer

Executive Director


FacebookTwitterLinkedinShare on Google+
Event D.jpg


Archived in
  Scientific News



Tagged in
FARA Scientific News